Skip to main
GILD

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences (GILD) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 47%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Gilead Sciences is a top biopharmaceutical company with a diverse portfolio focused on treating and preventing life-threatening infectious diseases like HIV and hepatitis B and C. With its recent acquisition of Pharmasset, Gilead has strengthened its oncology pipeline and is poised to grow its presence in the cancer market. The company's strong financials and promising pipeline make it a solid long-term investment option.

Bears say

Gilead Sciences is facing numerous challenges that are negatively impacting its outlook. The high levels of accrued government rebates and ongoing accquisitions and impairments are causing significant financial strain on the company. Additionally, the company is heavily reliant on its hepatitis and HIV portfolio, which is facing stiff competition and potential challenges in terms of intellectual property and patent protection. Gilead's recent clinical trial results have also been mixed, with one drug showing positive results while another experiencing major setbacks. This, coupled with ongoing legal risks and potential issues with patent protection, make Gilead a risky investment.

Gilead Sciences (GILD) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 47% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gilead Sciences (GILD) Forecast

Analysts have given Gilead Sciences (GILD) a Buy based on their latest research and market trends.

According to 15 analysts, Gilead Sciences (GILD) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $152.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $152.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gilead Sciences (GILD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.